These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era.. Mohapatra R; Tran M; Gore JM; Spencer FA Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146 [TBL] [Abstract][Full Text] [Related]
5. New blood thinner offers first potential alternative in 50 years: ximelagatran. Nutescu EA; Helgason CM; Briller J; Schwertz DW J Cardiovasc Nurs; 2004; 19(6):374-83. PubMed ID: 15529058 [TBL] [Abstract][Full Text] [Related]
7. Ximelagatran: an orally active direct thrombin inhibitor. Gulseth MP Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925 [TBL] [Abstract][Full Text] [Related]
8. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. Halperin JL J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364 [TBL] [Abstract][Full Text] [Related]
9. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. Halperin JL Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465 [TBL] [Abstract][Full Text] [Related]
11. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H; N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939 [TBL] [Abstract][Full Text] [Related]
12. [Future potential indications for an oral thrombin inhibitor]. Haas S Hamostaseologie; 2002 Aug; 22(3):36-43. PubMed ID: 12215760 [TBL] [Abstract][Full Text] [Related]
13. Ximelagatran--a promising new drug in thromboembolic disorders. Petersen P Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069 [TBL] [Abstract][Full Text] [Related]
14. Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Agnelli G Drugs; 2004; 64 Suppl 1():47-52. PubMed ID: 15586627 [TBL] [Abstract][Full Text] [Related]
15. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Evans HC; Perry CM; Faulds D Drugs; 2004; 64(6):649-78. PubMed ID: 15018597 [TBL] [Abstract][Full Text] [Related]
16. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Huisman MV; Bounameaux H Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915 [TBL] [Abstract][Full Text] [Related]
17. Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge? Mousa SA; Abdel-Razeq HN Cardiovasc Drug Rev; 2005; 23(4):331-44. PubMed ID: 16614732 [TBL] [Abstract][Full Text] [Related]
18. Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin. Kalus JS; Caron MF Expert Opin Investig Drugs; 2004 May; 13(5):465-77. PubMed ID: 15155122 [TBL] [Abstract][Full Text] [Related]
19. Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. Bergqvist D Eur J Haematol; 2004 Oct; 73(4):227-42. PubMed ID: 15347309 [TBL] [Abstract][Full Text] [Related]
20. Oral direct thrombin inhibitors in clinical development. Gustafsson D J Intern Med; 2003 Oct; 254(4):322-34. PubMed ID: 12974871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]